The first ten drugs covered under Medicare Part D have been chosen for negotiations to lower prices for Medicare enrollees. These drugs treat severe health conditions such as blood clots, diabetes, heart failure, and chronic kidney disease. According to data from the U.S. Department of Health and Human Resources, about 9 million Medicare Part D enrollees in 2022 used the drugs selected for price negotiations. According to the Centers for Medicare and Medicaid Services, these ten drugs accounted for $50.5 billion, or 20%, of total Medicare Part D gross covered prescription drug costs from June 1, 2022 to May 31, 2023. In 2022, Medicare Part D enrollees spent $3.4 billion in out-of-pocket costs on the above drugs. The average annual out-of-pocket spending in 2022 (for enrollees without financial assistance) ranged from a high of $6,497 per enrollee taking Imbruvica to a low of $261 per enrollee taking NovoLog. Of the ten drugs selected for price negotiations, Eliquis is the most widely used drug among Medicare Part D enrollees. Over 3.7 million enrollees used Eliquis between June 2022 and May 2023, costing Medicare around $16.5 billion. If the above drugs can be negotiated down in price, not only will the Medicare program itself see a reduction in spending, but enrollees will be paying less out-of-pocket. Price negotiations are an opportunity for people with Medicare to have access to life-saving treatments at a lower cost.